RetinalGeniX Technologies, Inc. operates as a medical device company. The company is headquartered in Petaluma, California and currently employs 0 full-time employees. The company went IPO on 2022-01-07. The firm's proprietary High-Resolution Retinal Imaging and DNA/RNA/GPS Pharmaco-Genetic Mapping technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular and metabolic systems, as well as diabetic conditions, Alzheimer’s disease and Parkinson’s disease. Its RetinalCam is an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians available 24/7. The company is also engaged in the development of its product candidates: RTG-2023 and RTG-2024. RTG-2023 for the treatment of dry age-related macular degeneration (dry AMD). RTG-2024 for the treatment of Alzheimer’s syndrome dementia.
Follow-Up Questions
RetinalGenix Technologies Inc のCEOは誰ですか？
Dr. Jerry Katzman は RetinalGenix Technologies Inc の President で、2018 から在籍しています。
RTGN の株価パフォーマンスは？
RTGN の現在の価格は $3.91 で、最終取引日から 0% decreased 変動しました。
RetinalGenix Technologies Inc の主な事業テーマや業界は？
RetinalGenix Technologies Inc は Health Care 業界、セクターは Health Care に属しています。
